Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNK-396
- Development stage
- Phase 1
- Lead developer
- Schnengkang Medical Technology
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
SNK-396 is an investigational oligonucleotide drug being developed for the treatment of elevated low-density lipoprotein cholesterol (LDL-C), primarily targeting hypercholesterolemia. The drug is administered subcutaneously and has completed Phase 1 clinical trials in adults and elderly patients with elevated LDL-C. The precise mechanism of action remains undefined, but it is classified as a new molecular entity. Development has been led by SynerK, with involvement from Schnengkang Medical Technology (Suzhou) Co., Ltd., and Syneos Health as collaborators in clinical studies[1][2][3][4].
- Other names
- SNK 396SNK396SNK-396
Beyond the preview
Go deeper on SNK-396.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNK-396.